This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter       

Oncology

18
Adding ipilimumab to nivolumab of little value in recurrent or metastatic head and neck SCC
Adding ipilimumab to nivolumab of little value in recurrent or metastatic head and neck SCC
Read more
Psilocybin therapy effective for major depression among cancer patients
Psilocybin therapy effective for major depression among cancer patients
Read more
GD2-CART01 effective for R/R high-risk neuroblastoma 
GD2-CART01 effective for R/R high-risk neuroblastoma 
Read more
Neoadjuvant socazolimab shows promise for locally advanced oesophageal squamous cell cancer
Neoadjuvant socazolimab shows promise for locally advanced oesophageal squamous cell cancer
Read more
Ide-cel provides 51% reduction in the risk of progression or death in R/R multiple myeloma
Ide-cel provides 51% reduction in the risk of progression or death in R/R multiple myeloma
Read more
Aggressive end-of-life care more common in nursing home compared to community residents
Aggressive end-of-life care more common in nursing home compared to community residents
Read more
Prostate cancer mortality no different in trial of three treatment interventions
Prostate cancer mortality no different in trial of three treatment interventions
Read more
DNA damage to oral cells similar in never smoking vapers and current smokers
DNA damage to oral cells similar in never smoking vapers and current smokers
Read more
Neoadjuvant pembrolizumab superior to adjuvant therapy in advanced resectable melanoma
Neoadjuvant pembrolizumab superior to adjuvant therapy in advanced resectable melanoma
Read more
Rucaparib offers survival advantage over usual care in metastatic prostate cancer
Rucaparib offers survival advantage over usual care in metastatic prostate cancer
Read more
Poor cardiovascular risk control identified in half of men with prostate cancer
Poor cardiovascular risk control identified in half of men with prostate cancer
Read more
Pembrolizumab shows benefit in high-risk BCG non-responsive bladder cancer
Pembrolizumab shows benefit in high-risk BCG non-responsive bladder cancer
Read more
T-VEC virotherapy and NAC improves response in triple negative breast cancer
T-VEC virotherapy and NAC improves response in triple negative breast cancer
Read more
Darolutamide improves overall survival in metastatic hormone sensitive prostate cancer
Darolutamide improves overall survival in metastatic hormone sensitive prostate cancer
Read more
Neoadjuvant nivolumab provides significant 5-year overall survival in lung cancer
Neoadjuvant nivolumab provides significant 5-year overall survival in lung cancer
Read more
RCT shows Ide-cel effective in refractory or relapsed multiple myeloma
RCT shows Ide-cel effective in refractory or relapsed multiple myeloma
Read more
Neoadjuvant chemotherapy improves 2 year survival in operable colon cancer
Neoadjuvant chemotherapy improves 2 year survival in operable colon cancer
Read more
Novel prostate cancer screening test highly accurate
Novel prostate cancer screening test highly accurate
Read more

Popular articles

Saliva test more accurate than PSA level or MRI for prostate cancer risk, study suggests
Expediting genomic testing pathways: analysis of the UKLCC lung cancer report
Prescribe ezetimibe with statins after myocardial infarction to improve prognosis, study suggests
Optimum timing for inhaler use to improve clinical outcomes identified by researchers
Troponin test ‘powerful indicator’ of cardiovascular risk, say researchers



 
FOLLOW US

IMPORTANT LINKS

MORE FROM COGORA

© Cogora 2025
Cogora Limited. 1 Giltspur Street, London EC1A 9DD Registered in the United Kingdom. Reg. No. 2147432

Cogora
x